文献速递肝病消化道肿瘤与早癌

HES V2.0在HEDS队列中的验证及与GALAD和ASAP的性能比较

HES V2.0 validation and performance compared to GALAD and ASAP in the HEDS cohort.
PubMed 文献 · J Hepatol · 2025-10-06

本研究在HEDS队列1485例肝硬化患者(其中119例发生HCC)中外部验证HES V2.0生物标志物面板,并比较其与HES V1.0、GALAD和ASAP的性能。HES V2.0与GALAD的AUROC均为0.79,但在固定10%假阳性率下,HES V2.0在HCC诊断前12个月灵敏度比GALAD高6.7%(单侧p=0.025);在可获得AFP、AFP-L3和DCP时间梯度数据的患者中,HES V2.0在所有时间点均优于GALAD。

要点

  • HES V2.0与GALAD的AUROC相同(0.79),但TPR/FPR特征不同。
  • 10% FPR下,HES V2.0在诊断前12个月灵敏度比GALAD高6.7%(p=0.025)。
  • 有纵向梯度数据时,HES V2.0在所有时间点优于GALAD。

核心结论

  • HES V2.0在肝硬化患者HCC早期检测中灵敏度优于ASAP,与GALAD相当或更优,尤其在诊断前12个月、10% FPR及具备时间梯度数据时。

研究设计与样本

  • PRoBE(前瞻性标本采集、回顾性盲法评估)队列研究,基于HEDS队列1485例肝硬化患者,其中119例发生HCC。

主要发现

  • HES V2.0与GALAD的AUROC均为0.79。
  • 10% FPR下,HES V2.0在HCC诊断前6、12、24个月的灵敏度分别比GALAD高2.0%、6.7%、6.0%(单侧p=0.24、0.025、0.078)。
  • 18.1% FPR下,GALAD在诊断前6和12个月的灵敏度分别比HES V2.0高6%和2%,24个月时两者相似(所有p>0.05)。
  • HES V2.0在12个月时灵敏度比HES V1.0高11.9%(p=0.007),比ASAP高10.9–16.3%。
  • 在具备计算时间梯度所需实验室数据的患者中,HES V2.0在所有时间点比GALAD高3.5–8.7%(相对增加8.7–24.0%,部分比较p<0.05)。

关键数值与推荐

  • 固定假阳性率(FPR)设为10%和18.1%(对应GALAD截断值-1.36),计算诊断前6、12、24个月的患者水平和检测水平真阳性率(TPR)。

临床怎么用

  • HES V2.0可整合入临床工作流程和未来试验,尤其当可获得AFP、AFP-L3和DCP的纵向数据时,可能改善高危患者HCC早期检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: We previously developed HES V2.0, a biomarker panel (age, ALT, platelets, etiology, AFP, AFP-L3, DCP, and their 1-year gradients) for early detection of hepatocellular carcinoma (HCC) among patients with cirrhosis. We externally validated HES V2.0 and compared its performance with HES V1.0, GALAD, and ASAP. METHODS: We conducted a PRoBE (prospective specimen-collection, retrospective blinded-evaluation) cohort study in the HEDS (Hepatocellular Carcinoma Early Detection Strategy) cohort of 1,485 patients with cirrhosis, of whom 119 developed HCC. Patient- and test-level true positive rates (TPR) for HCC were calculated at 6, 12, and 24 months before diagnosis, using thresholds at a fixed false positive rate (FPR) of 10% and 18.1% (corresponding to the GALAD cut-off of -1.36). RESULTS: HES V2.0 and GALAD had the same AUROC (0.79) but differed in TPR/FPR profiles. At 10% FPR, HES V2.0 achieved 2.0%, 6.7%, and 6.0% higher sensitivity than GALAD at 6, 12, and 24 months before HCC diagnosis (one-sided p = 0.24, 0.025, and 0.078, respectively). At 18.1% FPR, GALAD showed 6% and 2% higher sensitivity than HES V2.0 at 6 and 12 months, respectively, and similar sensitivity at 24 months (all p >0.05). HES V2.0 demonstrated 11.9% higher sensitivity than HES V1.0 at 12 months (p = 0.007) and 10.9-16.3% higher sensitivity than ASAP. In patients with the necessary laboratory data to calculate temporal gradients, HES V2.0 outperformed GALAD by 3.5-8.7% at all time points (an 8.7-24.0% relative increase; p <0.05 for several comparisons). CONCLUSIONS: In this phase III biomarker validation study, HES V2.0 showed higher sensitivity than ASAP and comparable or superior sensitivity to GALAD, particularly at 12 months before HCC diagnosis at 10% FPR and when temporal gradients in AFP, AFP-L3, and DCP were available. IMPACT AND IMPLICATIONS: Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality, with early detection being critical for improving survival outcomes. This study provides a rigorous phase III validation of the HES V2.0 biomarker panel, demonstrating its superior or comparable sensitivity to established models like GALAD and ASAP in a large, diverse cirrhosis cohort from the United States. The findings are particularly impactful for clinicians and researchers focused on liver cancer surveillance, as HES V2.0 offers enhanced detection performance, especially when longitudinal biomarker data are available. These results support the integration of HES V2.0 into clinical workflows and future trials, potentially improving early HCC detection and enabling timely curative interventions for at-risk patients.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. El-Serag HB, Lopez C, Luster M, et al. HES V2.0 validation and performance compared to GALAD and ASAP in the HEDS cohort. J Hepatol. 2025. PMID: 41043723. doi:10.1016/j.jhep.2025.09.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。